In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
|Articles|December 20, 2017
CTTI Selected to Support FDA Efforts to Increase Patient Engagement
Advertisement
CTTI is announcing it has been engaged by the FDA to support its Patient Engagement Collaborative. This collaborative aims at discussing ways in which patients can participate in the FDA's regulatory discussions about medical products. With patient feedback, this collaborative was created and will continue to be used in the future by bringing together representatives to discuss topics on how patients and the FDA can continue working with one another.
Read the full release
Advertisement
Related to this article
Mixed FSP and FSO models are gaining ground as sponsors seek agility and resource flexibility, but the oversight infrastructure, audit trails, and accountability structures needed to run them well and survive regulatory inspection are consistently lagging behind the model itself.
A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain underutilized despite their importance to interpretation.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
5